Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarshipNow a renewable award, students may earn the AbbVie Immunology Scholarship for up to four yearsRecipients live with conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis
Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growthIntroduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers
If approved, BOTOX® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle prominence and patient satisfaction with treatmentÂ
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0.17 Per Share Related to Acquired IPR&D and Milestones Expense
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē MembersThis summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approvalJoin Allē today to take advantage of limited time offers, while supplies last
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV)The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total body (T-VASI 50) and facial repigmentation (F-VASI 75) from baseline at week 48, versus placebo1
RINVOQ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA)Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score ≤ 20) and improvements in eyebrows and eyelashes at week 241RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBoey® offers a differentiated treatment option for many people who are curious about facial injectables²
SkinMedica® launches Regenerative Science Advisory Board to shape future innovationExpands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovationDebuts flagship retail experiences designed to support practice and patients' needs
Issued on behalf of Conexeu Sciences Inc.
